Please login to the form below

Not currently logged in
Email:
Password:

Burson-Marsteller appoint new EMEA health MD

Kate Hawker joins the agency from InforMed

Burson-Marsteller, Kate Hawker

Burson-Marsteller has appointed Kate Hawker as the new MD and chair of its EMEA and UK healthcare divisions.

“Kate is an excellent, and welcome, addition to Burson-Marsteller's outstanding group of EMEA practice chairs,” said Jeremy Galbraith, CEO of Burson-Marsteller EMEA.

“She brings the healthcare expertise and individual creativity that clients justifiably expect from a leading global agency and I am delighted she is joining us.”

She joins the agency after three years as business development director for InforMed, following the acquisition of her start-up medical communications company Medea.

During her 25-year career Hawker has directed pan-European and UK medical communications and PR programmes, having worked on campaigns for GSK, Baxter, Takeda, Boehringer-Ingelheim, Bristol Meyer Squibb, MSD and others.

She has also been a director and partner at Fleishman-Hillard, director at OCC and associate director for Shire Health International.


Commenting on her appointment, Hawker said: “I'm delighted to be joining Burson-Marsteller, an agency with a stand-out reputation for delivering integrated communications campaigns on a UK, EMEA and global level. I'm looking forward to working with a great team both in the UK and across EMEA.”

20th November 2012

From: Marketing, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics